Podcasts about association between

Join Dr. Riehl and Kate as they share practical lifestyle strategies for managing IBS with constipation. Studies show that up to 84% of IBS patients experience GI distress related to eating, with most triggers linked to carbohydrate intake—particularly highly fermentable ones like FODMAPs. Learn how the low FODMAP diet, the most extensively researched dietary approach for IBS, stacks up against traditional therapies and medications. Kate also explores other researched diet options for IBS, including the Mediterranean diet and the UK NICE IBS diet guidelines.Dr. Riehl discusses the intricate gut-brain connection and presents evidence-based therapies for managing IBS symptoms. She provides an in-depth review of a range of treatments, including mindfulness techniques, gut-directed hypnosis, and other effective interventions, offering a comprehensive approach to symptom relief.Finally, we explore simple, holistic lifestyle changes that can complement IBS management. From the benefits of eating a wide array of colorful plants, engaging in mindful eating, to stress reduction and healthy living techniques. By the end of this episode, you'll be equipped with a variety of self-care and nurturing practices that align with your personal values, helping you find joy, reduce stress, and better manage your IBS symptoms.Diaphragmatic breathing demonstrationBook: Real Self-Care: A Transformative Program for Redefining Wellness (Crystals, Cleanses, and Bubble Baths Not Includes)References:Nutrition:Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.The Association Between a Mediterranean Diet and Symptoms of Irritable Bowel SyndromeClinical Trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndromeUK Nice Guidelines IBSCAM & Sleep:Complementary and Alternative Therapies for Chronic ConstipationSleep Duration in ConstipationLearn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

A bit late, but worth the wait - this is a controversial discussion worth having. WHO should be using cannabis, and WHO may be experiencing unintended and unwanted consequences? Below are the citations for the research covered in this episode. This is not a comprehensive discussion of all of the nuances of cannabis use. As a reminder, I am not a medical doctor and this podcast is not intended to diagnose or treat medical conditions. Work with me at www.madreterra.love Urits I, Charipova K, Gress K, Li N, Berger AA, Cornett EM, Kassem H, Ngo AL, Kaye AD, Viswanath O. Adverse Effects of Recreational and Medical Cannabis. Psychopharmacol Bull. 2021 Jan 12;51(1):94-109. PMID: 33897066; PMCID: PMC8063125. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016 Sep;42(5):1262-9. doi: 10.1093/schbul/sbw003. Epub 2016 Feb 15. PMID: 26884547; PMCID: PMC4988731. Dhein S. Different Effects of Cannabis Abuse on Adolescent and Adult Brain. Pharmacology. 2020;105(11-12):609-617. doi: 10.1159/000509377. Epub 2020 Jul 6. PMID: 32629444. Carol EE, Spencer RL, Mittal VA. The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis. Psychoneuroendocrinology. 2017 Sep;83:58-64. doi: 10.1016/j.psyneuen.2017.04.017. Epub 2017 May 30. PMID: 28595088; PMCID: PMC5531192. Glodosky NC, Cuttler C, McLaughlin RJ. A review of the effects of acute and chronic cannabinoid exposure on the stress response. Front Neuroendocrinol. 2021 Oct;63:100945. doi: 10.1016/j.yfrne.2021.100945. Epub 2021 Aug 28. PMID: 34461155; PMCID: PMC8605997. Xia RJ, Chao T, Patel D, Bedi G. Responses to social evaluative stress in regular cannabis smokers. J Psychopharmacol. 2021 Jul;35(7):833-840. doi: 10.1177/0269881120972337. Epub 2021 Feb 7. PMID: 33554736; PMCID: PMC8996818. Rompala G, Nomura Y, Hurd YL. Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2106115118. doi: 10.1073/pnas.2106115118. PMID: 34782458; PMCID: PMC8617511. Cohen L, Neuman MG. Cannabis and the Gastrointestinal Tract. J Pharm Pharm Sci. 2020;23:301-313. doi: 10.18433/jpps31242. PMID: 32762830. Pizzol D, Demurtas J, Stubbs B, Soysal P, Mason C, Isik AT, Solmi M, Smith L, Veronese N. Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis. Am J Mens Health. 2019 Nov-Dec;13(6):1557988319892464. doi: 10.1177/1557988319892464. PMID: 31795801; PMCID: PMC6893937. Brown TT, Dobs AS. Endocrine effects of marijuana. J Clin Pharmacol. 2002 Nov;42(S1):90S-96S. doi: 10.1002/j.1552-4604.2002.tb06008.x. PMID: 12412841. Harclerode J. Endocrine effects of marijuana in the male: preclinical studies. NIDA Res Monogr. 1984;44:46-64. PMID: 6090909. https://www.zrtlab.com/blog/archive/the-effects-of-cannabis-on-your-hormones/ Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):270-8. doi: 10.1016/j.taap.2005.12.019. Epub 2006 Feb 24. PMID: 16499939.

Drs. Robert Whittington and Jean Wong discuss the article “Association Between the FRAIL Scale and Postoperative Complications in Older Surgical Patients: A Systematic Review and Meta-Analysis” published in the February 2023 issue of Anesthesia & Analgesia.

Interview with Ilana Doweck, MD, author of Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss, and Eric J. Formeister, MD, MS, author of Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination Hosted by Joseph P. Bradley, MD.

Interview with Ilana Doweck, MD, author of Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss, and Eric J. Formeister, MD, MS, author of Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination Hosted by Joseph P. Bradley, MD.

Interview with Ilana Doweck, MD, author of Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss, and Eric J. Formeister, MD, MS, author of Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination Hosted by Joseph P. Bradley, MD.

Cupom de desconto de 200 reais ===> SpfVoyBUPX (https://checkout.medway.com.br/vzW8JjIipE/SpfVoyBUPX) Link para o extensivo R3 de clínica médica da medway: https://r3.medway.com.br/clinica-medica/?utm_source=Social&utm_medium=BrandedContent&utm_campaign=ta-de-clinicagem Rapha, João e Fred discutem sobre a variante Omicron. O episódio é dividido em 3 partes: primeiro a discussão sobre as mudanças nas orientações de isolamento do Ministério da Saúde, segundo sobre a vacinação de reforço e a resposta vacinal com a nova variante, terceiro sobe os novos tratamentos de COVID-19 ambulatorial e atualizações sobre o tratamento hospitalar. Dá uma olhada nas "show notes" no nosso site tadeclinicagem.com.br Referências: Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus 2019 (Ministério da Saúde, janeiro de 2022) Uptodate Jan 2022. COVID-19: Vaccines. Kathryn M Edwards,Walter A Orenstein, Martin S Hirsch, Allyson Bloom, MD. ACCORSI, Emma K. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA, 2022. OMER, Saad B.; MALANI, Preeti N. Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach. JAMA, 2022. JOHNSON, Amelia G. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence—25 US Jurisdictions, April 4–December 25, 2021. MMWR. Morbidity and Mortality Weekly Report, v. 71, 2022. THOMPSON, Mark G. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance—VISION Network, 10 States, August 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report, v. 71, 2022. NEMET, Ital et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. New England Journal of Medicine, 2021. SIGAL, Alex. Milder disease with Omicron: is it the virus or the pre-existing immunity?. Nature Reviews Immunology, p. 1-3, 2022. CLEMENS, Sue Ann Costa et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet, 2022. GOTTLIEB, Robert L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine, 2021. KAWANO-DOURADO, Leticia; ROCHWERG, Bram. Therapeutics and COVID-19: living guideline. 2021. https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/medicamentos (acesso em 27/01/2022) CAO, Yunlong Richard et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. BioRxiv, 2021. RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 2021. GUPTA, Anil et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New England Journal of Medicine, v. 385, n. 21, p. 1941-1950, 2021. JAYK BERNAL, Angélica et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New England Journal of Medicine, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results Rhee, C., et al. "Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation?[manuscript published online ahead of print August 25 2020]." Clin Infect Dis (2020). Owusu, Daniel, et al. "Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A Cohort Study of Individuals with COVID-19." The Journal of Infectious Diseases (2021).

Association Between a Temporary Reduction in Access to Health Care and Long-term Changes in Hypertension Control Among Veterans After a Natural Disaster Aaron Baum, PhD; Michael L. Barnett,MD, MS; Juan Wisnivesky,MD, DrPH; Mark D. Schwartz, MD. JAMA Network Open. 2019;2(11):e1915111. doi:10.1001/jamanetworkopen.2019.15111 (Reprinted) November 13, 2019 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2755309

Episode Notes We continue with advice for new runners. John Richmond and I chat about running injuries in this episode. Not the big nasty ones but the minor niggles and irritations you have to learn to manage if you get into running. We'll cover the more serious ones in later episodes. The dreaded stitch 03:00 Shin splints 08:05 Muscle strains and injuries 11:58 Knee pain - anterior knee pain 18:10 Osteoarthritis of the knees 22:30 Links Chi Running by Danny Dreyer Is There an Association Between a History of Running and Symptomatic Knee Osteoarthritis? A Cross-Sectional Study From the Osteoarthritis Initiative. Podcast Promotion We’d love it if you could please share #Blokeology with your Twitter followers. You can do that by clicking here.  If you got something out of this episode then please mosey on over to Apple Podcasts and kindly leave us a rating, a review and you can subscribe there too! Other ways to subscribe to Blokeology Click here to subscribe via Apple Podcasts Click here to subscribe via RSS Click here to subscribe on Android You can also subscribe via Stitcher Sign up for the Journal of Blokeology newsletter It's my regular newsletter that shares some cool evidence-based health, fitness, and lifestyle advice. And get your free Healthy Bloke Action Plan. Head over to www.blokeology.io/journal to do that. Feedback I would love to hear from you and your own experiences. Best bet is to email: euan AT blokeology.io. Or there are numerous options via social media as well. You don't need me to point them out. Try these links: Twitter | Facebook | Instagram | Pinterest      

Fluids in Critical Care: Time to SPLIT With Normal Saline? Summary by: Paul Young Intravenous fluid therapy is a ubiquitous treatment for critically ill patients and has been used in clinical practice for over 175 years. Despite this long history, the majority of intravenous fluids have not been subjected to the same level of scrutiny as other drugs. That said, large-scale fluid trials evaluating albumin and starch solutions compared to 0.9% saline have been conducted and their results have changed clinical practice around the world so that crystalloid fluid therapy is now predominant in many parts of the world. While 0.9% saline is the world’s most commonly prescribed crystalloid fluid, increasingly clinicians are turning to buffered or balanced crystalloid solutions as an alternative to 0.9% saline. This practice change from 0.9% saline towards balanced crystalloids is not based on high quality evidence but is supported by observational data suggesting that saline may be associated with an increased risk of renal toxicity and mortality compared to buffered crystalloids. This talk gives an overview of the data comparing the comparative effectiveness of 0.9% saline and buffered crystalloids, provides an overview of the historical context of intravenous fluid therapy (and proctoclysis), and describes the design of the Saline vs. Plasma-Lyte 148® for Intravenous fluid Therapy (SPLIT) trial which has now been completed and was recently published in the Journal of the American Medical Association. External Links• [The Bottom line] SPLIT trial reviewed• [article] Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit The SPLIT Randomized Clinical Trial• [editorial] Editorial accompanying paper• [videocast] Presentation of SPLIT trial at ESICM by Dr Paul Young• [Further reading] Association Between a Chloride-Liberal vs Chloride-Restrictive Intravenous Fluid Administration Strategy and Kidney Injury in Critically Ill Adults• [St Emlyn's] SPLIT trial published. Saline or Plasmalyte on the ICU?

Interview with David M. Nathan, MD, author of Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality

Interview with Ziad Obermeyer, MD, MPhil, author of Association Between the Medicare Hospice Benefit and Health Care Utilization and Costs for Patients With Poor-Prognosis Cancer

Interview with Kevin L Winthrop, MD, MPH, author of Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster